About

Download the UH MacDonald Women’s Hospital Fact Sheet (PDF)

At a Glance

Opened in 1891 as the Maternity Hospital of Cleveland, today University Hospitals MacDonald Women’s Hospital is synonymous with excellence in clinical research, medicine and patient care. Located on the main campus of University Hospitals in University Circle, Cleveland, Ohio, UH MacDonald Women’s Hospital is Ohio’s only hospital dedicated solely to women’s health. Renowned as a leading center in women’s health research, UH MacDonald Women’s Hospital offers comprehensive care and the latest medical advancements through a dedicated, multidisciplinary team of experts in maternal fetal medicine, obstetrics and gynecology, female pelvic medicine and surgery, gynecologic oncology, reproductive endocrinology and infertility, behavioral medicine, minimally invasive gynecologic surgery and midwifery.

2015 Statistics

Hospital founded: 1891
Licensed adult beds: 93
Nursery bassinets: 48
Medical staff: 61
Residents/fellows: 29
Inpatient discharges (adult): 4,723
Births: 4,171
Outpatient visits: 72,943
Surgical cases: 2,294
Total days of care: 21,418
Average length of stay: 2.9
Charity care: $49 million (University Hospitals, 2014)

Quality outcomes/Evidence-based labor practices

Primary CD rate: 29 percent
(Primary cesarean rate in low-risk women. State average is 26.3 percent.)
Preterm delivery without medical indication: 1.8 percent (State average is 4.1 percent.)
Episiotomy: 2 percent (State average is 10.4 percent)
TOLAC/VBAC: 58 percent/78 percent
(Successful trial of labor/vaginal birth after cesarean. State average is 10.4 percent.)
Steroid administration for preterm delivery: 100 percent

Department chairman

James H. Liu, MD
Arthur H. Bill Professor
Case Western Reserve University School of Medicine

Address

University Hospitals Cleveland Medical Center
11100 Euclid Avenue
Cleveland, OH 44106
Phone: 216-844-3941

Awards

• Ranked one of America’s Best Hospitals for Gynecology by U.S. News & World Report
• 2015 Five Star winner in Ohio First Steps Breastfeeding Initiative (ODH/OHA)
• 2014 designated Baby Friendly by Baby Friendly USA

Medical/surgical services

• Behavioral Medicine
• Female Pelvic Medicine & Reconstructive Surgery
• General Obstetrics & Gynecology
• Gynecologic Oncology
• Maternal Fetal Medicine
• Midwifery
• Minimally Invasive Gynecologic Surgery
• Neonatology
• Reproductive Endocrinology & Infertility

Specialty programs and clinics

• Bleeding Disorders
• Centering Pregnancy
• Family Planning Center
• Preconception Planning Clinic
• Center for Diabetes in Pregnancy
• Pregnancy Diabetes Boot Camp
• Sexual Function & Vulvovaginal Health Center
• Menopause Clinic
• Centering Parenting
• Adolescent PCOS Clinic
• Pediatric & Adolescent Gynecology Clinic
• UH Fertility Center
• Sickle Cell Gynecology Clinic

National Institutes of Health Research and Extramural Grants

March of Dimes Prematurity Research Collaborative of Ohio
Co-Principal Investigator: Sam Mesiano, PhD

ERV3 Control of human placentation
Principal Investigator: Neal Rote, PhD

Role of nuclear progesterone receptors in the control of human parturition
Principal Investigator: Sam Mesiano, PhD

Development of gene-specific progesterone receptor modulators to prevent preterm birth
Principal Investigator: Sam Mesiano, PhD

Interferon-epsilon and hormonal contraceptive modulation of the risk of HIV acquisition
Principal Investigator: Sam Mesiano, PhD

Gynecologic Oncology Foundation
Principal Investigator: Steven Waggoner, MD

NRG Oncology
Principal Investigator: Steven Waggoner, MD

NCI National Clinical Trials Network (NCTN)
Lead Academic Participating Site (LAPS)
Gynecologic Oncology Team Leader: Steven Waggoner, MD

NICHD Contraceptive Clinical Trials Network
Principal Investigator: James Liu, MD

NICHD Maternal-Fetal Medicine Units (MFMU) Network Site
Principal Investigator: David Hackney, MD

Neurophysiologic & autonomic characterization of interstitial cystitis/painful bladder syndrome
Co-Principal Investigators: Jeffrey Janata, PhD, Sangeeta Mahajan, MD, and Adonis Hijaz, MD

A phase 3 study to evaluate the efficacy and safety of eagolix in combinations with estradiol/norethindrone acetate for the management of heavy menstrual bleeding associated with uterine fibroid in premenopausal women
Principal Investigator: Angelina Gangestad, MD

A phase 3 study to evaluate the safety and efficacy of elagolix in combination with estradiol/norethindrone acetate in subjects with moderate to severe endometriosis-associated pain
Principal Investigator: Angelina Gangestad, MD

A double-blind, randomized, parallel-group, placebo-controlled study of MLE4901 for the treatment of polycystic ovary syndrome (PCOS)
Principal Investigator: Angelina Gangestad, MD